Navigation Links
CareFusion to Resume Shipping Alaris(R) Infusion Products
Date:7/10/2009

SAN DIEGO, July 10 /PRNewswire/ -- CareFusion Corporation, the company that will become public from the planned spinoff of Cardinal Health's clinical and medical products businesses, today announced it will immediately resume customer implementations of its Alaris(R) PC units and PCA (Patient Controlled Analgesia) modules following a shipping hold announced in March.

The company is ready to resume shipments following 510(k) clearance from the Food and Drug Administration (FDA) for a software correction that will be implemented on new Alaris PC units.

"The 510(k) clearance for our software correction is another important milestone in our continued progress under the amended consent decree," said Dwight Winstead, chief operating officer of CareFusion. "We will continue to work closely with the FDA to fulfill all of our obligations under the amended consent decree and execute within our new quality system to manufacture products that are among the safest in the industry."

The 510(k) clearance follows FDA acceptance of the company's corrective action plan for field remediation of its infusion pumps that was announced on June 9. For Alaris PC units already with customers, CareFusion will begin implementing the software correction as part of this corrective action plan.

About CareFusion Corporation

CareFusion Corporation, a wholly owned subsidiary of Cardinal Health (NYSE: CAH), is expected to become a public company from the planned spinoff of Cardinal Health's clinical and medical products businesses. The global company serves the health care industry with products and services that help hospitals measurably improve the safety and quality of health care. CareFusion develops market-leading technologies including Alaris(R) IV pumps, Pyxis(R) automated dispensing and patient identification systems, AVEA and Pulmonetic Systems ventilation and respiratory products, ChloraPrep(R) and MedMined(TM) services for infection prevention, neurological monitoring and diagnostic products, V. Mueller(R) surgical instruments, and an extensive line of products that support interventional medicine.

CareFusion employs more than 15,000 people across its global operations and serves customers in 120 countries. The company has applied to have its shares of common stock listed on the New York Stock Exchange under the ticker symbol "CFN." More information may be found at www.carefusion.com.

Cautions Concerning Forward-Looking Statements

This news release contains forward-looking statements addressing the planned spinoff of Cardinal Health's clinical and medical products businesses as a separate company named CareFusion Corporation, which is dependent upon future events or developments. These matters are subject to risks and uncertainties that could cause actual events (including the planned spinoff) and results to differ materially from those projected, anticipated or implied. These risks and uncertainties include uncertainties regarding the planned spinoff of CareFusion, including the timing and terms of any such spinoff and whether such spinoff will be completed as it is subject to a number of conditions. In addition, Cardinal Health and CareFusion are subject to additional risks and uncertainties described in CareFusion's Form 10, as amended, and Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports. Except to the extent required by applicable law, Cardinal Health and CareFusion undertake no obligation to update or revise any forward-looking statement.


'/>"/>
SOURCE CareFusion Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CareFusion Corporation Files Form 10 Registration Statement
2. CareFusion Names Edward Borkowski as Chief Financial Officer
3. CareFusion Announces Board of Directors, Progress on Alaris Consent Decree
4. CareFusion Names Robert Friel to Board of Directors
5. CareFusion Launches New Brand, Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety
6. CareFusion Files Amended Form 10 Registration Statement With SEC
7. CareFusion Corporation Launches International Jazz Festival Series
8. Novadaq Resumes Normal Business Operations by Securing ICG for SPY
9. Douglas A. McClain, Jr. Resumes CFO Duties at Immunosyn
10. BioElectronics Corporations Commercial Resumes on Bloomberg Television
11. China Shenghuo to Resume Trading on NYSE Alternext US LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 ... ... Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/18/2017)... SAN DIEGO and BLOOMINGTON, ... Pharmaceuticals, Inc. (NASDAQ: IMMY ) ("Imprimis"), ... d/b/a Precision Lens ("Precision Lens"), today announced the ... Under the agreement, Precision Lens will deploy a ... into select geographies in the U.S., primarily focused ...
Breaking Medicine Technology: